Genelux GNLX
NASDAQ GNLX
$2.48 -0.04 (-1.59%)
At close: Sep 10, 2026 · 4:00 PM EDT

Genelux (GNLX) Income from Continuing Operations (2022 - 2026)

Genelux (GNLX) posted Income from Continuing Operations of -$9.0 million for Q1 2026, up 3.08% on a QoQ basis from -$9.3 million in Q4 2025, and down 17.9% year-over-year from -$11.0 million in Q1 2025.

Analysis

Genelux (GNLX) Income from Continuing Operations (2022 - 2026) Analysis & Trends

Genelux has reported Income from Continuing Operations for 5 years, with the latest figure at -$9.0 million in Q1 2026.

  • On a quarterly basis, Income from Continuing Operations fell 17.9% year-over-year to -$9.0 million in Q1 2026; TTM through Mar 2026 was -$33.9 million, a 10.59% decrease from a year earlier, with the FY2025 full-year figure at -$32.5 million, down 4.86% from the prior year.
  • Income from Continuing Operations was -$9.0 million for Q1 2026 at Genelux, up from -$9.3 million in the prior quarter.
  • The five-year high for Income from Continuing Operations was $4.9 million in Q3 2022, with the low at -$9.6 million in Q1 2023.
  • Average Income from Continuing Operations over 5 years is -$6.5 million, with a median of -$7.6 million recorded in 2025.
  • The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations tumbled 208.88% in 2023, then rose 17.99% in 2024.
  • Over 5 years, Income from Continuing Operations stood at -$3.5 million in 2022, then slumped by 93.62% to -$6.8 million in 2023, then slumped by 41.08% to -$9.5 million in 2024, then rose by 2.75% to -$9.3 million in 2025, then advanced by 3.08% to -$9.0 million in 2026.
  • The last three Income from Continuing Operations figures came in at -$9.0 million (Q1 2026), -$9.3 million (Q4 2025), and -$8.0 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 2.38 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn -10.50 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 1.10 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 1.30 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 601.00 Mn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn -782.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 164.49 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 97.50 Mn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -290.61 Mn
10 Genelux 108.17 Mn 108.17 Mn - -9.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -9.00 Mn
Dec 31, 2025 -9.28 Mn
Sep 30, 2025 -8.02 Mn
Jun 30, 2025 -7.57 Mn
Mar 31, 2025 -7.63 Mn
Dec 31, 2024 -9.55 Mn
Sep 30, 2024 -6.72 Mn
Jun 30, 2024 -6.73 Mn
Mar 31, 2024 -7.85 Mn
Dec 31, 2023 -6.77 Mn
Sep 30, 2023 -5.35 Mn
Jun 30, 2023 -5.42 Mn
Mar 31, 2023 -9.57 Mn
Dec 31, 2022 -3.50 Mn
Sep 30, 2022 4.91 Mn